Importantly, our findings reported here suggest that the activation of the NF-κB signaling pathway needs to be carefully considered when NAC1 inhibition is used in various therapies and that targeting the inhibition of NAC1 and the NF-κB pathway simultaneously would most likely be an improved and more effective approach for melanoma therapy. Here, NACC1 is linked to melanoma.